NCT07490860 A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial
| NCT ID | NCT07490860 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fred Hutchinson Cancer Center |
| Condition | Lung Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2026-08-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial develops and studies whether a restorative justice-based lung cancer screening (LCS) decision-making support intervention tailored for Black individuals increases LCS among Black community members. Lung cancer remains the leading cause of cancer deaths among Black men and women. LCS with yearly low-dose chest computed tomography (CT) is recommended for people with current or recent tobacco use (within 15 years) who are aged 50-80 with at least a 20 pack-year smoking history. LCS lowers lung cancer death by 20%; however, data shows that LCS completion remains low among minority groups in the United States. The restorative justice-based LCS decision-making support intervention in this trial has been specifically tailored to meet the needs of Black individuals. It is designed to reduce racial unfairness by promoting trust, shared understanding, and empowerment in clinical decision making while addressing the social and historical circumstances of health inequalities. This may be an effective way to increase LCS among Black community members.
Eligibility Criteria
Inclusion Criteria: * Identify as Black or African American * Between ages 50-77 * Self-reported 20-pack year smoking history * Ongoing commercial tobacco use within the past 15 years * Proficiency in the English language Exclusion Criteria: * Has a documented chest CT within the past one year * Personal history of lung cancer or symptoms associated with lung cancer
Contact & Investigator
Matthew Triplette, MD, MPH
PRINCIPAL INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Frequently Asked Questions
Who can join the NCT07490860 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 77 Years, studying Lung Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07490860 currently recruiting?
Yes, NCT07490860 is actively recruiting participants. Contact the research team at Mtriplet@fredhutch.org for enrollment information.
Where is the NCT07490860 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT07490860 clinical trial?
NCT07490860 is sponsored by Fred Hutchinson Cancer Center. The principal investigator is Matthew Triplette, MD, MPH at Fred Hutch/University of Washington Cancer Consortium. The trial plans to enroll 45 participants.